EUVIMEDEUVIMED entdecken
Crossref

Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy

Christopher R Defilippi, Wendimagegn G Alemayehu, Adriaan A Voors, David Kaye, Robert O Blaustein, Javed Butler, Justin A Ezekowitz, Adrian F Hernandez, Carolyn S P Lam, Lothar Roessig, Stephen Seliger, Palak Shah und 4 weitere

Journal of Cardiac Failure · 2023

DOI: 10.1016/j.cardfail.2022.12.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2023. Verfasst von Christopher R Defilippi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Inova Heart and Vascular Institute, Falls Church, Virginia. Electronic address: Christopher.Defilippi@Inova.org. Hauptthemen laut MEDLINE: Heart Failure, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Merck & Co Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Circulating biomarkers may be useful in understanding prognosis and treatment efficacy in heart failure with reduced ejection fraction. In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, vericiguat, a soluble guanylate cyclase stimulator, decreased the primary outcome of cardiovascular death or heart failure hospitalization in heart failure with reduced ejection fraction. We evaluated biomarkers of cardiac injury, inflammation, and renal function for associations with outcomes and vericiguat treatment effect. METHODS AND RESULTS: High-sensitivity cardiac troponin T (hs-cTnT), growth differentiation factor-15 (GDF-15), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and cystatin C were measured at baseline and 16 weeks. Associations of biomarkers with the primary outcome and its components were estimated. Interaction with study treatment was tested. Changes in biomarkers over time were examined by study treatment. One or more biomarkers were measured in 4652 (92%) of 5050 participants at baseline and 4063 (81%) at 16 weeks. After adjustment, higher values of hs-cTnT, growth differentiation factor-15, and interleukin-6 were associated with the primary outcome, independent of N-terminal pro-B-type natriuretic peptide. Higher hs-cTnT values were associated with a hazard ratio per log standard deviation of 1.21 (95% confidence interval 1.14-1.27). A treatment interaction with vericiguat was evident with hs-cTnT and cardiovascular death (P = .04), but not HF hospitalization (P = .38). All biomarkers except cystatin C decreased over 16 weeks and no relationship between treatment assignment and changes in biomarker levels was observed. CONCLUSIONS: hs-cTnT, growth differentiation factor-15, and interleukin-6 levels were associated with risk of the primary outcome in VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction). Uniquely, lower hs-cTnT was associated with a lower rate of cardiovascular death but not HF hospitalization after treatment with vericiguat.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureVentricular Dysfunction, LeftHumansCystatin CInterleukin-6BiomarkersInflammationNatriuretic Peptide, BrainKidneyGrowth Differentiation FactorsTroponin TStroke Volume

Stichwörter der Autor:innen

Heart failure with reduced ejection fractioncirculating biomarkersvericiguat

Substanzen

Cystatin CInterleukin-6BiomarkersNatriuretic Peptide, BrainGrowth Differentiation FactorsTroponin T

Autor:innen und Institutionen

  • Inova Heart and Vascular Institute, Falls Church, Virginia. Electronic address: Christopher.Defilippi@Inova.org.
  • Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
  • University of Groningen, University Medical Center of Groningen, Groningen, the Netherlands.
  • Baker Heart & Diabetes Institute, Melbourne, Australia.
  • Merck & Co., Inc., Rahway, New Jersey.
  • Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi.

Förderung

  • Merck & Co Inc

Zitieren

APA

Defilippi, C. R., Alemayehu, W. G., Voors, A. A., Kaye, D., Blaustein, R. O., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., Roessig, L., Seliger, S., Shah, P., Westerhout, C. M., Armstrong, P. W., O'Connor, C. M., & VICTORIA Study Group (2023). Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2022.12.013

Vancouver

Defilippi CR, Alemayehu WG, Voors AA, Kaye D, Blaustein RO, Butler J, et al. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy. Journal of Cardiac Failure. 2023. doi:10.1016/j.cardfail.2022.12.013

BibTeX
@article{Defilippi2023,
  author = {Defilippi, Christopher R and Alemayehu, Wendimagegn G and Voors, Adriaan A and Kaye, David and Blaustein, Robert O and Butler, Javed and Ezekowitz, Justin A and Hernandez, Adrian F and Lam, Carolyn S P and Roessig, Lothar and Seliger, Stephen and Shah, Palak and Westerhout, Cynthia M and Armstrong, Paul W and O'Connor, Christopher M and VICTORIA Study Group, VICTORIA Study Group},
  title = {Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy},
  journal = {Journal of Cardiac Failure},
  year = {2023},
  doi = {10.1016/j.cardfail.2022.12.013}
}
Kostenlos starten →